Status:
COMPLETED
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
Lead Sponsor:
Helsinki University Central Hospital
Conditions:
Hypertension
Pharmacogenetics
Eligibility:
MALE
35-59 years
Phase:
PHASE4
Brief Summary
Blood pressure variation and the risk of essential hypertension have an important genetic component. In most cases susceptibility to essential hypertension is likely determined by the action of more t...
Detailed Description
Blood pressure variation and the risk of essential hypertension have an important genetic component. In most cases susceptibility to essential hypertension is likely determined by the action of more t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- essential hypertension diagnosed on an earlier occasion or during the present study (three diastolic blood pressure readings \>=95 mmHg on separate occasions are required).
- Exclusion Criteria (before and during the study):
- usage of three or more antihypertensive drugs
- secondary hypertension
- left ventricular hypertrophy
- drug-treated diabetes mellitus
- coronary heart disease
- stroke and other disorders of cerebral circulation
- renal disease
- obstructive pulmonary disease
- a disease treated with corticosteroids
- a disease with drug treatment potentially influencing blood pressure levels
- significant obesity (BMI \>=32 kg/m2)
- allergic reaction towards any of the study drugs
- The patient is excluded from the study if his blood pressure level rises to 200/120 mmHg or above during the study.
Exclusion
Key Trial Info
Start Date :
November 25 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT03276598
Start Date
November 25 1999
End Date
April 1 2004
Last Update
September 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland